Skip to main content
. 2013 Dec;87(23):12562–12575. doi: 10.1128/JVI.00871-13

Table 3.

Neutralization potencies and binding avidities of group-reactive human anti-E MAbs in this study

MAb Patient ID, immune statusa Neutralization potency (FRNT50 value) (μg/ml)
Kd (μg/ml)b
D1 D2 D3 D4
DVG1.3 DVG, primary D1 1 0.25 >1 1 0.021 ± 0.002
DVG6.3 DVG, primary D1 >1 1 >1 >1 0.397 ± 0.078
DVG7.5 DVG, primary D1 1 1 >1 >1 0.777 ± 0.048
DVG12.2 DVG, primary D1 >1 >1 >1 1 0.684 ± 0.052
DVD19.4 DVD, primary D4 >1 1 >1 0.25 0.199 ± 0.027
DVD19.13 DVD, primary D4 1 0.25 >1 1 0.296 ± 0.037
DVD23.3 DVD, primary D4 1 1 >1 0.25 0.207 ± 0.019
DVD23.4 DVD, primary D4 >1 0.25 1 1 0.234 ± 0.024
DVD26.3 DVD, primary D4 >1 1 >1 1 0.509 ± 0.056
DVD26.11 DVD, primary D4 >1 >1 >1 >1 1.878 ± 0.178
DVC23.13 DVC, primary D2 1 1 1 1 0.065 ± 0.005
DVB64.31 DVB, primary D3 1 >1 >1 >1 0.360 ± 0.030
749B2 749, secondary D1 1 0.25 1 0.25 0.052 ± 0.005
749B4 749, secondary D1 0.063 0.25 >1 0.016 0.043 ± 0.003
749B6 749, secondary D1 1 1 >1 >1 0.032 ± 0.002
749B12 749, secondary D1 0.063 0.25 1 0.016 0.034 ± 0.003
751A1 751, secondary D1 0.25 0.25 0.25 0.25 0.047 ± 0.003
751A2 751, secondary D1 0.25 0.25 1 1 0.097 ± 0.005
751A12 751, secondary D1 1 1 >1 1 0.052 ± 0.007
751B3 751, secondary D1 1 0.25 1 1 0.105 ± 0.009
751B6 751, secondary D1 0.063 0.063 0.83 1 0.025 ± 0.002
751B11 751, secondary D1 0.25 0.25 1 0.25 0.013 ± 0.001
751B12 751, secondary D1 1 0.25 1 0.25 0.022 ± 0.001
751C4 751, secondary D1 0.25 0.063 0.31 0.25 0.011 ± 0.001
751C10 751, secondary D1 0.063 0.063 1 0.063 0.019 ± 0.003
753A1 753, secondary D1 1 0.25 >1 1 0.130 ± 0.010
753C1 753, secondary D1 0.25 0.063 0.25 0.25 0.015 ± 0.001
753C6 753, secondary D1 0.063 0.063 1 0.25 0.024 ± 0.002
753C8 753, secondary D1 1 0.25 1 1 0.063 ± 0.004
753C12 753, secondary D1 0.25 0.063 0.25 0.063 0.035 ± 0.003
750C9 750, secondary D1 0.25 1 >1 1 0.296 ± 0.030
750D7 750, secondary D1 1 0.25 >1 1 0.070 ± 0.006
a

The immune status (primary or secondary DENV infection) and infecting serotype of patients were determined as reported previously (22, 29). D, DENV.

b

The Kd was determined by DENV1 virion-capture ELISA as described in Materials and Methods.